Nuvation Bio Inc.

NUVB

Held by 4 specialist biotech funds

High Convergence

Share on X

Fund Holdings

4 fund convergence

Rock Springs Capital Redmile Group EcoR1 Capital

Catalysts

No catalysts tracked.

Position Details

Rock Springs CapitalNEWFeb 17, 2026

Shares: 134,028Value: $44K

# Signal Note: Rock Springs Capital Initiates NUVB Position Rock Springs' modest $44K entry into Nuvation Bio suggests conviction in the company's clinical pipeline, likely centered on NUV-422 (a potassium channel modulator in development for autosomal dominant polycystic kidney disease) or earlier-stage assets. The concentrated long/short specialist's initiation signals belief in upcoming clinical readouts or partnering catalysts that could re-rate the biotech's currently depressed valuation. Monitor for Phase 2 ADPKD trial updates or M&A activity as near-term catalysts.

Redmile GroupNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

NGNE3 funds IMNM3 funds GPCR3 funds XENE3 funds COGT3 funds BBIO3 funds NBIX2 funds MIRM

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

AI Signal

AI analyst context — unlock full analysis

# Signal Note: Redmile Group Initiates NUVB Position Redmile's $28.3M entry into Nuvation Bio signals conviction in the company's clinical pipeline, likely anchored on NUV-422 (GLP-1 receptor agonist for metabolic dysfunction-associated fatty liver disease/MASLD) which is progressing through Phase 2b. Green's healthcare crossover expertise suggests confidence in the commercial thesis around obesity/metabolic disease, though near-term catalysts depend on 2024-2025 trial readouts and regulatory feedback on the competitive GLP-1 landscape.